$26.5 Billion is the total value of Baker Brothers Advisors's 126 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 20.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Seagen Inc. | $8,278,767,000 | -10.5% | 47,269,424 | 0.0% | 31.19% | -15.6% | |
| BGNE | Sell | BeiGene, Ltd.sponsored adr | $3,015,126,000 | -20.9% | 11,668,897 | -12.3% | 11.36% | -25.4% |
| INCY | Buy | Incyte Corporation | $2,783,337,000 | -3.1% | 31,999,741 | +0.0% | 10.49% | -8.6% |
| ACAD | ACADIA Pharmaceuticals Inc. | $2,240,219,000 | +29.6% | 41,904,586 | 0.0% | 8.44% | +22.2% | |
| KOD | Buy | Kodiak Sciences Inc. | $2,039,104,000 | +178.8% | 13,879,952 | +12.4% | 7.68% | +162.9% |
| ALXN | Alexion Pharmaceuticals, Inc. | $1,368,786,000 | +36.5% | 8,760,794 | 0.0% | 5.16% | +28.7% | |
| PRLD | Prelude Therapeutics Incorporated | $723,988,000 | +137.5% | 10,118,636 | 0.0% | 2.73% | +124.0% | |
| BMRN | BioMarin Pharmaceutical Inc. | $665,505,000 | +15.3% | 7,589,294 | 0.0% | 2.51% | +8.7% | |
| NVTA | Buy | Invitae Corporation | $654,292,000 | +27.4% | 15,649,182 | +32.0% | 2.46% | +20.1% |
| ASND | Ascendis Pharma A/Ssponsored adr | $590,446,000 | +8.1% | 3,540,270 | 0.0% | 2.22% | +1.9% | |
| ABCL | New | AbCellera Biologics Inc. | $420,515,000 | – | 10,450,180 | +100.0% | 1.58% | – |
| MRTX | Mirati Therapeutics, Inc. | $309,645,000 | +32.3% | 1,409,784 | 0.0% | 1.17% | +24.8% | |
| ARGX | argenx SEsponsored adr | $299,842,000 | +12.0% | 1,019,557 | 0.0% | 1.13% | +5.6% | |
| IGMS | Buy | IGM Biosciences, Inc. | $277,663,000 | +19.6% | 3,144,892 | +0.0% | 1.05% | +12.8% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $166,668,000 | -6.4% | 1,499,213 | 0.0% | 0.63% | -11.7% | |
| AMRN | Sell | Amarin Corporation plcsponsored adr | $136,880,000 | +1.5% | 27,991,761 | -12.6% | 0.52% | -4.3% |
| HRTX | Heron Therapeutics, Inc. | $126,878,000 | +42.8% | 5,994,704 | 0.0% | 0.48% | +34.6% | |
| KYMR | Kymera Therapeutics, Inc. | $121,471,000 | +91.9% | 1,959,211 | 0.0% | 0.46% | +81.0% | |
| ALLK | Buy | Allakos Inc. | $99,995,000 | +75.8% | 714,250 | +2.3% | 0.38% | +66.1% |
| CERS | Cerus Corporation | $94,895,000 | +10.5% | 13,713,195 | 0.0% | 0.36% | +4.4% | |
| BCRX | BioCryst Pharmaceuticals, Inc. | $94,584,000 | +116.9% | 12,695,818 | 0.0% | 0.36% | +104.6% | |
| PACB | Sell | Pacific Biosciences of California, Inc. | $83,059,000 | +158.9% | 3,201,972 | -1.5% | 0.31% | +144.5% |
| ZYME | Zymeworks Inc. | $80,742,000 | +1.5% | 1,708,472 | 0.0% | 0.30% | -4.4% | |
| INSM | Sell | Insmed Incorporated | $71,773,000 | -1.7% | 2,156,001 | -5.1% | 0.27% | -7.5% |
| FMTX | Buy | Forma Therapeutics Holdings, Inc. | $70,668,000 | -20.0% | 2,024,876 | +14.3% | 0.27% | -24.6% |
| RYTM | Sell | Rhythm Pharmaceuticals, Inc. | $68,821,000 | +28.5% | 2,314,873 | -6.3% | 0.26% | +21.0% |
| NBIX | Neurocrine Biosciences, Inc. | $64,888,000 | -0.3% | 676,975 | 0.0% | 0.24% | -6.2% | |
| AXSM | Sell | Axsome Therapeutics, Inc. | $63,452,000 | -7.2% | 778,834 | -18.9% | 0.24% | -12.5% |
| RARE | New | Ultragenyx Pharmaceutical Inc. | $61,524,000 | – | 444,444 | +100.0% | 0.23% | – |
| NRIX | Nurix Therapeutics, Inc. | $58,820,000 | -5.8% | 1,788,921 | 0.0% | 0.22% | -11.2% | |
| BCEL | Atreca, Inc. | $57,054,000 | +15.6% | 3,532,760 | 0.0% | 0.22% | +9.1% | |
| NLTX | Neoleukin Therapeutics, Inc. | $53,887,000 | +17.5% | 3,821,740 | 0.0% | 0.20% | +10.9% | |
| ADAP | Buy | Adaptimmune Therapeutics plcsponsored adr | $52,988,000 | +4.9% | 9,830,877 | +55.3% | 0.20% | -1.0% |
| APLS | Apellis Pharmaceuticals, Inc. | $51,283,000 | +89.6% | 896,551 | 0.0% | 0.19% | +78.7% | |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | $49,469,000 | +15.3% | 2,799,577 | 0.0% | 0.19% | +8.8% | |
| ADCT | Sell | ADC Therapeutics SA | $45,394,000 | -18.5% | 1,418,107 | -16.0% | 0.17% | -23.0% |
| ALGS | New | Aligos Therapeutics, Inc. | $44,517,000 | – | 1,610,000 | +100.0% | 0.17% | – |
| HZNP | Sell | Horizon Therapeutics Public Ltd Co | $43,825,000 | -15.4% | 599,110 | -10.1% | 0.16% | -20.3% |
| KRYS | Sell | Krystal Biotech, Inc. | $41,932,000 | +25.7% | 698,874 | -9.8% | 0.16% | +18.8% |
| CCXI | Sell | ChemoCentryx, Inc. | $40,663,000 | -17.5% | 656,710 | -27.0% | 0.15% | -22.3% |
| GBT | Global Blood Therapeutics, Inc. | $39,861,000 | -21.5% | 920,375 | 0.0% | 0.15% | -26.1% | |
| DBVT | DBV Technologies S.A.sponsored adr | $38,289,000 | +51.4% | 14,614,264 | 0.0% | 0.14% | +42.6% | |
| OPT | New | Opthea Limitedsponsored ads | $37,107,000 | – | 3,308,705 | +100.0% | 0.14% | – |
| MRUS | Merus N.V. | $35,717,000 | +46.1% | 2,037,469 | 0.0% | 0.14% | +37.8% | |
| ALKS | Buy | Alkermes plc | $30,626,000 | +36.0% | 1,535,149 | +13.0% | 0.12% | +27.8% |
| FREQ | Sell | Frequency Therapeutics, Inc. | $30,200,000 | +65.6% | 856,507 | -9.8% | 0.11% | +56.2% |
| PTGX | Sell | Protagonist Therapeutics, Inc. | $28,954,000 | -7.2% | 1,436,192 | -10.0% | 0.11% | -12.8% |
| BCAB | New | BioAtla, Inc. | $28,058,000 | – | 825,000 | +100.0% | 0.11% | – |
| RETA | Buy | Reata Pharmaceuticals, Inc.cl a | $27,688,000 | +434.4% | 223,976 | +321.1% | 0.10% | +395.2% |
| ATHA | Sell | Athira Pharma, Inc. | $27,618,000 | +69.6% | 806,367 | -8.6% | 0.10% | +60.0% |
| AGLE | Sell | Aeglea BioTherapeutics, Inc. | $26,838,000 | -13.6% | 3,410,106 | -22.1% | 0.10% | -18.5% |
| FLGT | Sell | Fulgent Genetics, Inc. | $25,819,000 | +18.1% | 495,573 | -9.3% | 0.10% | +11.5% |
| ADPT | Sell | Adaptive Biotechnologies Corporation | $22,451,000 | +4.8% | 379,682 | -13.8% | 0.08% | -1.2% |
| MREO | New | Mereo BioPharma Group plcads | $21,588,000 | – | 6,030,293 | +100.0% | 0.08% | – |
| VSTM | New | Verastem, Inc. | $21,607,000 | – | 10,144,039 | +100.0% | 0.08% | – |
| ALT | Sell | Altimmune, Inc. | $21,257,000 | -27.0% | 1,884,451 | -14.6% | 0.08% | -31.0% |
| IMTX | Buy | Immatics N.V. | $19,476,000 | +83.3% | 1,805,025 | +80.2% | 0.07% | +73.8% |
| AUPH | Sell | Aurinia Pharmaceuticals Inc. | $19,501,000 | -18.2% | 1,410,064 | -12.9% | 0.07% | -23.2% |
| NVAX | Sell | Novavax, Inc. | $18,924,000 | -6.8% | 169,706 | -9.4% | 0.07% | -12.3% |
| IDRA | Idera Pharmaceuticals, Inc. | $16,914,000 | +71.5% | 4,608,786 | 0.0% | 0.06% | +64.1% | |
| CBAY | Sell | Cymabay Therapeutics, Inc. | $16,607,000 | -29.5% | 2,893,276 | -11.0% | 0.06% | -33.0% |
| Invitae Corporationnote 2.0% 9/1/2024 | $16,446,000 | -2.7% | 10,300,000 | 0.0% | 0.06% | -8.8% | ||
| XNCR | Sell | Xencor, Inc. | $16,116,000 | +1.3% | 369,370 | -9.9% | 0.06% | -4.7% |
| BioMarin Pharmaceutical Inc.note 0.599% 8/1/2024 | $16,033,000 | +2.4% | 15,000,000 | 0.0% | 0.06% | -4.8% | ||
| ALBO | Sell | Albireo Pharma, Inc. | $15,472,000 | -15.6% | 412,466 | -24.9% | 0.06% | -20.5% |
| SGMO | Sell | Sangamo Therapeutics, Inc. | $13,379,000 | +49.1% | 857,339 | -9.7% | 0.05% | +38.9% |
| GMDA | Buy | Gamida Cell Ltd. | $12,990,000 | +394.3% | 1,548,314 | +144.5% | 0.05% | +345.5% |
| GWPH | Sell | GW Pharmaceuticals plcads | $13,029,000 | -3.5% | 112,897 | -18.6% | 0.05% | -9.3% |
| KDNY | New | Chinook Therapeutics, Inc. | $11,874,000 | – | 748,693 | +100.0% | 0.04% | – |
| FPRX | New | Five Prime Therapeutics, Inc. | $11,363,000 | – | 668,000 | +100.0% | 0.04% | – |
| MIRM | Buy | Mirum Pharmaceuticals, Inc. | $11,302,000 | +6.1% | 647,313 | +17.1% | 0.04% | 0.0% |
| SBTX | New | Silverback Therapeutics, Inc. | $11,033,000 | – | 238,095 | +100.0% | 0.04% | – |
| XENE | Sell | Xenon Pharmaceuticals Inc. | $10,572,000 | +25.6% | 687,386 | -9.6% | 0.04% | +17.6% |
| BLUE | Sell | bluebird bio, Inc. | $9,822,000 | -27.8% | 226,988 | -9.9% | 0.04% | -31.5% |
| ISEE | IVERIC bio, Inc. | $9,716,000 | +22.5% | 1,406,037 | 0.0% | 0.04% | +15.6% | |
| ASMB | Assembly Biosciences, Inc. | $9,326,000 | -63.2% | 1,541,418 | 0.0% | 0.04% | -65.3% | |
| ANAB | Sell | AnaptysBio, Inc. | $9,184,000 | +27.8% | 427,179 | -12.3% | 0.04% | +20.7% |
| CRNX | Buy | Crinetics Pharmaceuticals, Inc. | $8,699,000 | +83.6% | 616,520 | +103.9% | 0.03% | +73.7% |
| VXRT | Sell | Vaxart, Inc. | $7,987,000 | -23.3% | 1,398,795 | -10.7% | 0.03% | -28.6% |
| CABA | Cabaletta Bio, Inc. | $7,942,000 | +15.1% | 636,363 | 0.0% | 0.03% | +7.1% | |
| HOOK | HOOKIPA Pharma Inc. | $7,768,000 | +17.1% | 700,481 | 0.0% | 0.03% | +7.4% | |
| DNLI | Sell | Denali Therapeutics Inc. | $7,433,000 | +108.7% | 88,738 | -10.7% | 0.03% | +100.0% |
| SYRS | Syros Pharmaceuticals, Inc. | $7,488,000 | +22.7% | 690,167 | 0.0% | 0.03% | +16.7% | |
| KRTX | Sell | Karuna Therapeutics, Inc. | $7,108,000 | +18.2% | 69,966 | -10.0% | 0.03% | +12.5% |
| AUTL | Buy | Autolus Therapeutics plcsponsored ads | $6,993,000 | +30.2% | 782,183 | +69.6% | 0.03% | +23.8% |
| HRMY | Sell | Harmony Biosciences Holdings, Inc. | $6,507,000 | -52.0% | 180,000 | -55.0% | 0.02% | -53.7% |
| GTH | Buy | Genetron Holdings Limitedads | $6,374,000 | +433.8% | 455,306 | +355.3% | 0.02% | +380.0% |
| PASG | Sell | Passage Bio, Inc. | $6,018,000 | +75.8% | 235,362 | -9.8% | 0.02% | +64.3% |
| NTLA | Sell | Intellia Therapeutics, Inc. | $6,055,000 | +149.2% | 111,296 | -9.0% | 0.02% | +130.0% |
| REPL | Sell | Replimune Group, Inc. | $5,856,000 | +23.1% | 153,512 | -25.7% | 0.02% | +15.8% |
| ITOS | Sell | Iteos Therapeutics, Inc. | $5,085,000 | +23.0% | 150,346 | -10.3% | 0.02% | +11.8% |
| TARA | Protara Therapeutics, Inc. | $4,834,000 | +43.9% | 199,671 | 0.0% | 0.02% | +38.5% | |
| BNR | Sell | Burning Rock Biotech Limitedsponsored ads | $4,831,000 | -18.8% | 209,131 | -11.9% | 0.02% | -25.0% |
| GOSS | New | Gossamer Bio, Inc. | $4,649,000 | – | 480,729 | +100.0% | 0.02% | – |
| TCDA | New | Tricida, Inc. | $4,437,000 | – | 629,300 | +100.0% | 0.02% | – |
| MGNX | New | MacroGenics, Inc. | $4,588,000 | – | 200,679 | +100.0% | 0.02% | – |
| IFRX | Sell | Inflarx N.V. | $4,307,000 | +0.3% | 856,228 | -15.0% | 0.02% | -5.9% |
| ALEC | Sell | Alector, Inc. | $3,620,000 | +29.4% | 239,228 | -9.9% | 0.01% | +27.3% |
| LOGC | New | LogicBio Therapeutics, Inc. | $3,445,000 | – | 451,478 | +100.0% | 0.01% | – |
| TCRR | Sell | TCR2 Therapeutics Inc. | $3,430,000 | +37.8% | 110,888 | -9.5% | 0.01% | +30.0% |
| NGM | Sell | NGM Biopharmaceuticals, Inc. | $3,230,000 | +71.9% | 106,616 | -9.7% | 0.01% | +50.0% |
| CHMA | Chiasma, Inc. | $3,228,000 | +1.2% | 742,133 | 0.0% | 0.01% | -7.7% | |
| LEGN | Sell | Legend Biotech Corporationsponsored ads | $3,256,000 | -17.7% | 115,626 | -9.8% | 0.01% | -25.0% |
| CNST | Sell | Constellation Pharmaceuticals, Inc. | $3,304,000 | +22.3% | 114,735 | -13.9% | 0.01% | +9.1% |
| AKRO | Sell | Akero Therapeutics, Inc. | $3,054,000 | -24.7% | 118,378 | -10.2% | 0.01% | -25.0% |
| XLRN | Sell | Acceleron Pharma Inc. | $2,870,000 | -0.5% | 22,430 | -12.5% | 0.01% | -8.3% |
| INZY | Sell | Inozyme Pharma, Inc. | $2,208,000 | -29.1% | 106,999 | -9.7% | 0.01% | -33.3% |
| OVID | Buy | Ovid Therapeutics Inc. | $2,208,000 | -34.9% | 955,690 | +61.8% | 0.01% | -42.9% |
| DRNA | Sell | Dicerna Pharmaceuticals, Inc. | $2,250,000 | +10.6% | 102,121 | -9.7% | 0.01% | 0.0% |
| VKTX | Sell | Viking Therapeutics, Inc. | $2,049,000 | -12.9% | 363,980 | -10.0% | 0.01% | -11.1% |
| RCUS | Sell | Arcus Biosciences, Inc. | $1,888,000 | -4.6% | 72,709 | -37.0% | 0.01% | -12.5% |
| ORTX | Sell | Orchard Therapeutics plcads | $1,436,000 | +1.8% | 332,502 | -3.1% | 0.01% | -16.7% |
| MTEM | Sell | Molecular Templates, Inc. | $1,257,000 | -22.6% | 133,833 | -10.1% | 0.01% | -16.7% |
| LPTX | Leap Therapeutics, Inc. | $1,259,000 | +13.6% | 559,705 | 0.0% | 0.01% | +25.0% | |
| INFI | Sell | Infinity Pharmaceuticals, Inc. | $1,107,000 | +63.0% | 522,360 | -10.0% | 0.00% | +33.3% |
| OYST | Sell | Oyster Point Pharma, Inc. | $1,156,000 | -19.7% | 61,424 | -10.0% | 0.00% | -33.3% |
| EVFM | Sell | Evofem Biosciences, Inc. | $991,000 | -3.0% | 411,396 | -5.0% | 0.00% | 0.0% |
| AFMD | Sell | Affimed N.V. | $958,000 | +49.0% | 164,605 | -13.3% | 0.00% | +33.3% |
| GLPG | Sell | Galapagos NVsponsored adr | $1,107,000 | -37.1% | 11,180 | -9.9% | 0.00% | -42.9% |
| Bellicum Pharmaceuticals, Inc. | $879,000 | -46.3% | 249,123 | 0.0% | 0.00% | -57.1% | ||
| KZR | Sell | Kezar Life Sciences, Inc. | $729,000 | -73.8% | 139,676 | -75.7% | 0.00% | -72.7% |
| GLMD | Sell | Galmed Pharmaceuticals Ltd. | $575,000 | -20.7% | 184,927 | -10.0% | 0.00% | -33.3% |
| ADMS | Sell | Adamas Pharmaceuticals, Inc. | $641,000 | -5.0% | 147,996 | -9.7% | 0.00% | -33.3% |
| QURE | Sell | uniQure N.V. | $244,000 | -96.6% | 6,740 | -96.5% | 0.00% | -96.6% |
| SNSS | Exit | Sunesis Pharmaceuticals, Inc. | $0 | – | -53,066 | -100.0% | 0.00% | – |
| SNSS | New | Sunesis Pharmaceuticals, Inc. | $106,000 | – | 53,066 | +100.0% | 0.00% | – |
| GNFT | Sell | Genfit SAads | $71,000 | -52.7% | 14,720 | -48.2% | 0.00% | -100.0% |
| ARAV | Exit | Aravive, Inc. | $0 | – | -75,854 | -100.0% | -0.00% | – |
| APLT | Exit | Applied Therapeutics, Inc. | $0 | – | -38,034 | -100.0% | -0.00% | – |
| CPRX | Exit | Catalyst Pharmaceuticals, Inc. | $0 | – | -474,400 | -100.0% | -0.01% | – |
| UROV | Exit | Urovant Sciences Ltd. | $0 | – | -978,505 | -100.0% | -0.04% | – |
| IMMU | Exit | Immunomedics, Inc. | $0 | – | -237,694 | -100.0% | -0.08% | – |
| Exit | Neurocrine Biosciences, Inc.note 2.25% 5/15/2024 | $0 | – | -30,770,000 | -100.0% | -0.17% | – | |
| EXAS | Exit | Exact Sciences Corporation | $0 | – | -1,846,139 | -100.0% | -0.75% | – |
| MYOK | Exit | MyoKardia, Inc. | $0 | – | -3,009,344 | -100.0% | -1.64% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.